ArticleThe European respiratory journal2025
Effectiveness and safety of tofacitinib
Article in The European respiratory journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Clinical characteristics and prognostic markers of anti-MDA5 antibody-positive dermatomyositis-associated interstitial lung disease: a retrospective cohort study.Journal of thoracic disease · 2026Article
- From 'Me too' to 'Me better' and 'Me cooler': the recent rheumatology advances in China.EULAR rheumatology open · 2026Review
- Article
- Distinct anti-MDA5 antibody trajectories associated with long-term outcomes in 6-month survivors of anti-MDA5 dermatomyositis with interstitial lung disease.Respiratory research · 2026Article
- Janus kinase and calcineurin-inhibitor combination in anti-MDA5 dermatomyositis: No significant survival benefit but reassuring safety profile.Journal of internal medicine · 2026Article
- Novel phenotypes of immune-mediated necrotizing myopathy identified independent of myositis-specific antibody specificity that improve prognostic stratification.Frontiers in immunology · 2026Article
- Targeted therapy against recurrent anti-synthetase syndrome associated interstitial lung disease after bilateral lung transplantation guided by transcriptomic analyses: a case-based study.Frontiers in immunology · 2026Article
- Case Report: Glucocorticoids with Early Aggressive Rituximab and Upadacitinib regimen in the treatment of three patients with anti-MDA5 dermatomyositis-associated interstitial lung disease.Frontiers in medicine · 2026Article
- Reduced peripheral CD4Frontiers in immunology · 2026Article
- Serum metabolic characteristics of interstitial lung disease: a potential link between endocrine aging and gut-derived metabolites.Frontiers in medicine · 2026Article
- Combination of tofacitinib and tacrolimus therapy in refractory interstitial lung disease associated with anti-synthetase syndrome: a case series of six patients.Frontiers in immunology · 2026Article
- Clinical features and prognostic factors of anti-MDA5 antibody-positive dermatomyositis-associated interstitial lung disease with spontaneous mediastinal emphysema: a retrospective case series of nine patients.Frontiers in medicine · 2026Article
- Type I interferon pathway activation in connective tissue disease associated interstitial lung disease.Frontiers in immunology · 2026Review
- Prognostic factors and a nomogram for survival in anti-MDA5 antibody-positive dermatomyositis-associated interstitial lung disease.BMC pulmonary medicine · 2025Article
- Baricitinib could improve the prognosis of anti-MDA5 antibody positive dermatomyositis associated interstitial lung disease.Arthritis research & therapy · 2025Article
- Recent advances in immunological mechanisms and murine disease models of idiopathic inflammatory myopathies.Inflammation and regeneration · 2025Review
- Spontaneous pneumomediastinum and/or pneumothorax in anti-MDA5 dermatomyositis: a refined staging system.Respiratory research · 2025Article
- Anti-interferon-α antibodies associate with disease activity and prognosis in anti-MDA5-positive dermatomyositis.Arthritis research & therapy · 2025Article
- How to treat patients with MDA5-associated rapidly progressive interstitial lung disease? Which immunosuppressive therapy for which patients?The European respiratory journal · 2025Article
- Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare the effectiveness and safety of tofacitinib
methodsAdult Chinese patients with newly diagnosed MDA5
resultsIn the eligible cohort, a total of 94 (32.4%) and 105 (46.7%) patients died or underwent lung transplantation within 1 year in the tofacitinib group (n=290) and the CNI group (n=225), respectively. After adjustment by IPTW, patients' lung transplantation-free survival rate within 1 year was significantly higher in the tofacitinib group compared to the CNI group (log-rank p=0.013). Multivariable Cox analysis performed in the IPTW dataset revealed that the hazard ratio of tofacitinib
conclusionIn this large multicentre cohort study, tofacitinib showed significantly more benefits for 1-year lung transplantation-free survival than calcineurin inhibitors in MDA5
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.